Premium
A prospective audit of cost of sedation, analgesia and neuromuscular blockade in a large British ICU
Author(s) -
AlHaddad M.,
Hayward I.,
Walsh T. S.
Publication year - 2004
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.2004.03961.x
Subject(s) - medicine , alfentanil , interquartile range , sedation , intensive care unit , anesthesia , sedative , propofol , prospective cohort study , pharmacy , emergency medicine , neuromuscular blockade , intensive care medicine , surgery , nursing
Summary Bottom‐up costs of sedative, analgesic and neuromuscular blocking drugs used in the intensive care unit have not been reported. We performed a prospective audit of the cost of these drugs using a bottom‐up approach by prospectively recording the daily amount of drugs administered to patients over a 3‐month period. Of 172 admissions, complete data were collected for 155 (92%). Propofol and alfentanil were the drugs most commonly used, being administered to 136 (88%) and 106 (68%) patients, respectively. The total cost was £14 070, which was 81% of the pharmacy figure (based on central purchasing). Ninety‐four per cent of the cost was for drugs administered to the 50% of patients who stayed in the intensive care unit longer than 48 h. The median (interquartile range [range]) cost per day was £9.30 (3.60–20.10 [0–61.20]). This represents less than 1% of reported total daily cost of intensive care per patient.